Ethynylcytidine

Ethynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis, inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancer[1][2][3]. Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[180300-43-0]

Product Name Alternative

ECyD; TAS-106; 3'-C-Ethynylcytidine

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Ethynylcytidine.html

Concentration

10mM

Purity

99.97

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

OC[C@@H]1[C@](O)(C#C)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1

Molecular Formula

C11H13N3O5

Molecular Weight

267.24

Precautions

H302, H315, H319, H335

References & Citations

[1]Shimamoto Y, et al. Antitumor activity and pharmacokinetics of TAS-106, 1- (3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine. Jpn J Cancer Res. 2001 Mar;92 (3) :343-51.|[2]Abdelrahim M, et al. TAS-106: preclinical, clinical and beyond. Oncology. 2013;85 (6) :356-363.|[3]Hammond-Thelin LA, et al. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. Invest New Drugs. 2012;30 (1) :316-326.